Completing three years of collaboration, we value strategic partnerships for scientific advancement, with the goal of pushing scientific boundaries and impacting patients’ lives. Our collaboration will continue to progress.
To support an ecosystem of innovation for the benefit of human health and well-being, NUVISAN brings innovators and investors together and creates discussion and potential collaboration for drug discovery projects. We congratulate ARGO Therapeutics on being the first winner of the 1st NUVISAN Drug Discovery Innovation Challenge.
From small-scale feasibility studies to large-scale GMP-compliant production, our team is specialized in radiolabeling APIs with different isotopes including stable isotope labeled NCEs (D, 13C, 15N) and radioactive labeled NCEs or peptides (3H, 14C), to support preclinical and clinical studies.
For targeted metabolomics assays, NUVISAN can now provide reproducible analysis for up to 630 metabolites and lipids per biological sample (usually 10 µl is sufficient) including both human and animal plasma, serum, tissue, feces, breast milk, cells and more.
NUVISAN ICB GmbH, a fully integrated contract research service provider for drug discovery and development (“NUVISAN ICB”), announced today that the company has received a grant from the Bill & Melinda Gates Foundation (Seattle, WA, USA, “the foundation”) for an integrated program on discovery and early development of novel non-hormonal contraceptive medicines.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture clinical batches of HT-001 topical drug product for its upcoming CLEER-001 clinical trial for cancer patients. HT-001 is a novel topical therapy in development for treatment of cutaneous toxicities associated with Epidermal Growth Factor Receptor (EGFR) inhibitor cancer therapy.
The NUVISAN group, a Contract Research Organization (CRO) and Contract Manufacturing Organization (CDMO), and ALS Limited, a global company in the testing, inspection and certification business, today announced the signing of a long term strategic partnership to open new markets. ALS Limited invests into a 49% stake of the NUVISAN group to expand its life sciences portfolio. The global testing specialist with its headquarters in Brisbane/ Australia supports NUVISAN's expansion strategy with its worldwide network.
NUVISAN and Innovation Campus Berlin now virtually gathered under one roof
We are delighted to officially announce the launch of our brand new website, www.nuvisan.com, providing our visitors with an easier way to learn about all NUVISAN’s solutions from the early drug discovery with target identification to the proof of concept in patient.
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and NUVISAN Innovation Campus Berlin (ICB) GmbH, a fully integrated contract research service provider for drug discovery and early development programs, today announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
INNOVATION CAMPUS BERLIN is a proud Partner of Europe’s Largest Initiative to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats which is launched today in cooperation with the European Union, the European Federation of Pharmaceutical Industries, Associations (EFPIA) companies and IMI-Associated Partners.
On the 1st of July, the "INNOVATION CAMPUS BERLIN" (ICB), a subsidiary of NUVISAN GmbH/ Neu-Ulm officially opened. NUVISAN has taken over a large part of the Berlin-based pharmaceutical research unit, focused on the field of small molecule active ingredients, from Bayer AG and agreed on a strategic partnership.
Das Pharma-Service Unternehmen NUVISAN hat mit Bayer die Übernahme eines großen Teils der in Berlin ansässigen Pharmaforschung auf dem Gebiet kleinmolekularer Wirkstoffe vereinbart und komplettiert damit sein Leistungsspektrum auf dem Gebiet der präklinischen Forschung.